The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Clinical experiences with systemically administered siRNA-based therapeutics in cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Self-citationStrategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Knocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115
Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,505
Self-citationAccumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., Terada, Y., Kano, M. R., Miyazono, K., Uesaka, M., et al. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.166 · Cited by 2,429
Delivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A. (2006) · Nature · doi:10.1038/nature04791 · Cited by 1,677
Cancer Exosomes Perform Cell-Independent MicroRNA Biogenesis and Promote Tumorigenesis
Melo, S. A., Sugimoto, H., O’Connell, J. T., Kato, N., Villanueva, A., Vidal, A., Qiu, L., Vitkin, E., Perelman, L. T., Melo, C. A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.005 · Cited by 1,531
Prabhakar, U., Maeda, H., Jain, R. K., Sevick-Muraca, E. M., Zamboni, W., Farokhzad, O. C., Barry, S. T., Gabizon, A., Grodzinski, P., & Blakey, D. C. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4561 · Cited by 1,485
Multifunctional Nanoparticles: Cost Versus Benefit of Adding Targeting and Imaging Capabilities
Cheng, Z., Al Zaki, A., Hui, J. Z., Muzykantov, V. R., & Tsourkas, A. (2012) · Science · doi:10.1126/science.1226338 · Cited by 1,322
Interfering with disease: a progress report on siRNA-based therapeutics
de Fougerolles, A., Vornlocher, H.-P., Maraganore, J., & Lieberman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2310 · Cited by 1,203
Nair, J. K., Willoughby, J. L. S., Chan, A., Charisse, K., Alam, M. R., Wang, Q., Hoekstra, M., Kandasamy, P., Kel’in, A. V., Milstein, S., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505986a · Cited by 1,141
Davis, M. E. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900015y · Cited by 977
Self-citationSafety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
MicroRNA silencing for cancer therapy targeted to the tumour microenvironment
Cheng, C. J., Bahal, R., Babar, I. A., Pincus, Z., Barrera, F., Liu, C., Svoronos, A., Braddock, D. T., Glazer, P. M., Engelman, D. M., et al. (2015) · Nature · doi:10.1038/nature13905 · Cited by 823
RNA interference in the clinic: challenges and future directions
Pecot, C. V., Calin, G. A., Coleman, R. L., Lopez-Berestein, G., & Sood, A. K. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2966 · Cited by 820
RNA-Based Therapeutics: Current Progress and Future Prospects
Burnett, J. C., & Rossi, J. J. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.008 · Cited by 819
Bartlett, D. W., Su, H., Hildebrandt, I. J., Weber, W. A., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707461104 · Cited by 803
Self-citationDicer, Drosha, and Outcomes in Patients with Ovarian Cancer
Merritt, W. M., Lin, Y. G., Han, L. Y., Kamat, A. A., Spannuth, W. A., Schmandt, R., Urbauer, D., Pennacchio, L. A., Cheng, J.-F., Nick, A. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0803785 · Cited by 712
Tabernero, J., Shapiro, G. I., LoRusso, P. M., Cervantes, A., Schwartz, G. K., Weiss, G. J., Paz-Ares, L., Cho, D. C., Infante, J. R., Alsina, M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0429 · Cited by 698
Progress towards in Vivo Use of siRNAs
Behlke, M. A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.001 · Cited by 677
Investigating the optimal size of anticancer nanomedicine
Tang, L., Yang, X., Yin, Q., Cai, K., Wang, H., Chaudhury, I., Yao, C., Zhou, Q., Kwon, M., Hartman, J. A., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411499111 · Cited by 654
Investigating the Impact of Nanoparticle Size on Active and Passive Tumor Targeting Efficiency
Sykes, E. A., Chen, J., Zheng, G., & Chan, W. C. W. (2014) · ACS Nano · doi:10.1021/nn500299p · Cited by 635
Maier, M. A., Jayaraman, M., Matsuda, S., Liu, J., Barros, S., Querbes, W., Tam, Y. K., Ansell, S. M., Kumar, V., Qin, J., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.124 · Cited by 625
Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity
Whitehead, K. A., Dorkin, J. R., Vegas, A. J., Chang, P. H., Veiseh, O., Matthews, J., Fenton, O. S., Zhang, Y., Olejnik, K. T., Yesilyurt, V., et al. (2014) · Nature Communications · doi:10.1038/ncomms5277 · Cited by 615
Bartlett, D. W. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj439 · Cited by 592
Fitzgerald, K., Frank-Kamenetsky, M., Shulga-Morskaya, S., Liebow, A., Bettencourt, B. R., Sutherland, J. E., Hutabarat, R. M., Clausen, V. A., Karsten, V., Cehelsky, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61914-5 · Cited by 577
Harrington, K. J., Mohammadtaghi, S., Uster, P. S., Glass, D. M., Peters, A. M., Vile, R. G., & Stewart, J. S. W. (2001) · PubMed · Cited by 575
Hu-Lieskovan, S., Heidel, J. D., Bartlett, D. W., Davis, M. E., & Triche, T. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0565 · Cited by 567
Self-citationCancer nanomedicines: So many papers and so few drugs!
Venditto, V. J., & Szoka, F. C. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.038 · Cited by 537
Intercellular Communication by Exosome-Derived microRNAs in Cancer
Hannafon, B., & Ding, W.-Q. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140714240 · Cited by 515
Nanoparticle Hydrophobicity Dictates Immune Response
Moyano, D. F., Goldsmith, M., Solfiell, D. J., Landesman-Milo, D., Miranda, O. R., Peer, D., & Rotello, V. M. (2012) · Journal of the American Chemical Society · doi:10.1021/ja2108905 · Cited by 478
Chemical Modification of siRNAs for In Vivo Use
Behlke, M. A. (2008) · Oligonucleotides · doi:10.1089/oli.2008.0164 · Cited by 454
Zuckerman, J. E., Gritli, I., Tolcher, A., Heidel, J. D., Lim, D., Morgan, R., Chmielowski, B., Ribas, A., Davis, M. E., & Yen, Y. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411393111 · Cited by 427
Self-citationHeidel, J. D., Yu, Z., Liu, J. Y.-C., Rele, S. M., Liang, Y., Zeidan, R. K., Kornbrust, D. J., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701458104 · Cited by 382
Self-citationPolycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane
Zuckerman, J. E., Choi, C. H. J., Han, H., & Davis, M. E. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200718109 · Cited by 372
Self-citationsiRNA Targeted to p53 Attenuates Ischemic and Cisplatin-Induced Acute Kidney Injury
Molitoris, B. A., Dagher, P. C., Sandoval, R. M., Campos, S. B., Ashush, H., Fridman, E., Brafman, A., Faerman, A., Atkinson, S. J., Thompson, J. D., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008111204 · Cited by 337
Golan, T., Khvalevsky, E. Z., Hubert, A., Gabai, R. M., Hen, N., Segal, A., Domb, A., Harari, G., David, E. B., Raskin, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4183 · Cited by 336
Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice
Judge, A. D., Robbins, M., Tavakoli, I., Levi, J., Hu, L., Fronda, A., Ambegia, E., McClintock, K., & MacLachlan, I. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37515 · Cited by 336
Suetsugu, A., Honma, K., Saji, S., Moriwaki, H., Ochiya, T., & Hoffman, R. M. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.08.007 · Cited by 317
A status report on RNAi therapeutics
Vaishnaw, A. K., Gollob, J., Gamba-Vitalo, C., Hutabarat, R., Sah, D., Meyers, R., de Fougerolles, T., & Maraganore, J. (2010) · Silence · doi:10.1186/1758-907x-1-14 · Cited by 297
Pennisi, E. (2013) · Science · doi:10.1126/science.341.6148.833 · Cited by 287
RNAi Therapies: Drugging the Undruggable
Wu, S. Y., Lopez-Berestein, G., Calin, G. A., & Sood, A. K. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008362 · Cited by 273
Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research
Egusquiaguirre, S. P., Igartua, M., Hernández, R. M., & Pedraz, J. L. (2012) · Clinical and Translational Oncology · doi:10.1007/s12094-012-0766-6 · Cited by 268
Schultheis, B., Strumberg, D., Santel, A., Vank, C., Gebhardt, F., Keil, O., Lange, C., Giese, K., Kaufmann, J., Khan, M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.55.0376 · Cited by 260
Phase I Study of a Systemically Delivered p53 Nanoparticle in Advanced Solid Tumors
Senzer, N., Nemunaitis, J., Nemunaitis, D., Bedell, C., Edelman, G., Barve, M., Nunan, R., Pirollo, K. F., Rait, A., & Chang, E. H. (2013) · Molecular Therapy · doi:10.1038/mt.2013.32 · Cited by 236
Weiss, G. J., Chao, J., Neidhart, J. D., Ramanathan, R. K., Bassett, D., Neidhart, J. A., Choi, C. H. J., Chow, W., Chung, V., Forman, S. J., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-012-9921-8 · Cited by 230
Self-citationProgress Toward In Vivo Use of siRNAs-II
Rettig, G. R., & Behlke, M. A. (2012) · Molecular Therapy · doi:10.1038/mt.2011.263 · Cited by 217
Cuellar, T. L., Barnes, D., Nelson, C., Tanguay, J., Yu, S.-F., Wen, X., Scales, S. J., Gesch, J., Davis, D., van Brabant Smith, A., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1362 · Cited by 213
Sioud, M. (2006) · European Journal of Immunology · doi:10.1002/eji.200535708 · Cited by 201
Koukourakis, M. I., Koukouraki, S., Giatromanolaki, A., Archimandritis, S. C., Skarlatos, J., Beroukas, K., Bizakis, J. G., Retalis, G., Karkavitsas, N., & Helidonis, E. S. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3512 · Cited by 191
Physical Chemistry of Nanomedicine: Understanding the Complex Behaviors of Nanoparticles in Vivo
Lane, L. A., Qian, X., Smith, A. M., & Nie, S. (2015) · Annual Review of Physical Chemistry · doi:10.1146/annurev-physchem-040513-103718 · Cited by 175
Systemic Delivery of a miR34a Mimic as a Potential Therapeutic for Liver Cancer
Daige, C. L., Wiggins, J. F., Priddy, L., Nelligan-Davis, T., Zhao, J., & Brown, D. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0209 · Cited by 168
Bartlett, D. W., & Davis, M. E. (2008) · Biotechnology and Bioengineering · doi:10.1002/bit.21668 · Cited by 164
Self-citationHeidel, J. D., Liu, J. Y.-C., Yen, Y., Zhou, B., Heale, B. S. E., Rossi, J. J., Bartlett, D. W., & Davis, M. E. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2218 · Cited by 160
Self-citationBartlett, D. W., & Davis, M. E. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.21285 · Cited by 153
Self-citationEliasof, S. D., Lazarus, D. D., Peters, C. G., Case, R. I., Cole, R. O., Hwang, J., Schluep, T., Chao, J., Lin, J. L., Yen, Y., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309566110 · Cited by 147
Self-citationStrumberg, D., Schultheis, B. S., Traugott, U., Vank, C., Santel, A., Keil, O., Giese, K., Kaufmann, J., & Drevs, J. (2011) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp50076 · Cited by 137
Gene Silencing by Double‐Stranded RNA (Nobel Lecture)
Fire, A. Z. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200701979 · Cited by 137
Stability Study of Unmodified siRNA and Relevance to Clinical Use
Hickerson, R. P., Vlassov, A. V., Wang, Q., Leake, D., Ilves, H., González-González, E., Contag, C. H., Johnston, B. H., & Kaspar, R. L. (2008) · Oligonucleotides · doi:10.1089/oli.2008.0149 · Cited by 136
Safety profile of RNAi nanomedicines
Barros, S. A., & Gollob, J. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.06.007 · Cited by 125
Beyond BRAF: where next for melanoma therapy?
Fedorenko, I. V., Gibney, G. T., Sondak, V. K., & Smalley, K. S. M. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.476 · Cited by 117
Development of siRNA Payloads to Target KRAS -Mutant Cancer
Yuan, T. L., Fellmann, C., Lee, C.-S., Ritchie, C. D., Thapar, V., Lee, L. C., Hsu, D. J., Grace, D., Carver, J. O., Zuber, J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0900 · Cited by 113
Potential clinical applications of siRNA technique: benefits and limitations
Chen, S., & Zhaori, G. (2010) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02400.x · Cited by 107
Long-Distance Communication between Laryngeal Carcinoma Cells
Antanavičiūtė, I., Rysevaitė, K., Liutkevičius, V., Marandykina, A., Rimkutė, L., Sveikatienė, R., Uloza, V., & Skeberdis, V. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099196 · Cited by 104
Tolcher, A. W., Rodrigueza, W. V., Rasco, D. W., Patnaik, A., Papadopoulos, K. P., Amaya, A., Moore, T. D., Gaylor, S. K., Bisgaier, C. L., Sooch, M., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2361-0 · Cited by 89
In vivo disassembly of IV administered siRNA matrix nanoparticles at the renal filtration barrier
Naeye, B., Deschout, H. G., Caveliers, V., Descamps, B., Braeckmans, K., Vanhove, C., Demeester, J., Lahoutte, T., Smedt, S. C. D., & Raemdonck, K. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.11.058 · Cited by 87
Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs
Song, G. K., Wu, H., Yoshino, K., & Zamboni, W. C. (2012) · Journal of Liposome Research · doi:10.3109/08982104.2012.655285 · Cited by 81
Dienstmann, R., Patnaik, A., Garcia-Carbonero, R., Cervantes, A., Benavent, M., Roselló, S., Tops, B. B. J., van der Post, R. S., Argilés, G., Skartved, N. J. Ø., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1432 · Cited by 77
Koldehoff, M., Steckel, N. K., Beelen, D. W., & Elmaagacli, A. H. (2007) · Clinical and Experimental Medicine · doi:10.1007/s10238-007-0125-z · Cited by 69
Toxicity profiling of several common RNAi-based nanomedicines: a comparative study
Landesman‐Milo, D., & Peer, D. (2013) · Drug Delivery and Translational Research · doi:10.1007/s13346-013-0158-7 · Cited by 68
The Dicey Role of Dicer: Implications for RNAi Therapy
Merritt, W. M., Bar‐Eli, M., & Sood, A. K. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2536 · Cited by 68
Challenges and Opportunities for Local and Systemic Delivery of siRNA and Antisense Oligonucleotides
Sepp‐Lorenzino, L., & Ruddy, M. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.174 · Cited by 65
Stable assembly of HIV-1 export complexes occurs cotranscriptionally
Nawroth, I., Mueller, F., Basyuk, E. I., Beerens, N., Rahbek, U. L., Darzacq, X., Bertrand, É., Kjems, J., & Schmidt, U. (2013) · RNA · doi:10.1261/rna.038182.113 · Cited by 61
Antisense therapeutics in oncology: current status
Farooqı, A. A., Marwat, Z., & Muntané, J. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s49652 · Cited by 55
Vesicle Trafficking and RNA Transfer Add Complexity and Connectivity to Cell–Cell Communication
Roberts, C. T., & Kurre, P. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0265 · Cited by 51
Heterogeneity in Nanoparticles Influences Biodistribution and Targeting
Adjei, I. M., Peetla, C., & Labhasetwar, V. D. (2013) · Nanomedicine · doi:10.2217/nnm.13.70 · Cited by 47
Zuckerman, J. E., Hsueh, T., Koya, R. C., Davis, M. E., & Ribas, A. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.310 · Cited by 44
Self-citationInaba, S., Nagahara, S., Makita, N., Tarumi, Y., Ishimoto, T., Matsuo, S., Kadomatsu, K., & Takei, Y. (2012) · Molecular Therapy · doi:10.1038/mt.2011.221 · Cited by 41
Zhang, J., Pei, Y., Zhang, H., Wang, L., Arrington, L., Zhang, Y., Glass, A., & Leone, A. M. (2012) · Molecular Pharmaceutics · doi:10.1021/mp3005337 · Cited by 38
Tumor vasculature is a key determinant for the efficiency of nanoparticle-mediated siRNA delivery
Li, L., Wang, R., Wilcox, D. M., Zhao, X. B., Song, J. C., Li, X., Kohlbrenner, W. M., Fesik, S. W., & Shen, Y. (2011) · Gene Therapy · doi:10.1038/gt.2011.146 · Cited by 34
(2014) · Nature Biotechnology · doi:10.1038/nbt.3045 · Cited by 34
Barrett, S. E., Burke, R. S., Abrams, M. T., Bason, C., Busuek, M., Carlini, E. J., Carr, B., Crocker, L. S., Fan, H., Garbaccio, R. M., et al. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.028 · Cited by 31
Ramanathan, R. K., Hamburg, S. I., Borad, M. J., et al. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-lb-289 · Cited by 31
Prognostic Significance of Deregulated Dicer Expression in Breast Cancer
Caffrey, E., Ingoldsby, H., Wall, D., Webber, M., Dinneen, K., Murillo, L. S., Inderhaug, C., Newell, J., Gupta, S., & Callagy, G. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083724 · Cited by 30
Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology
Gomes-da-Silva, L. C., Simões, S., & Moreira, J. N. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1502-2 · Cited by 29
Robbins, G. R., Roberts, R. A., Guo, H., Reuter, K., Shen, T. W., Sempowski, G. D., McKinnon, K. P., Su, L., DeSimone, J. M., & Ting, J. P. ‐. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2014.11.010 · Cited by 15
Tissue-specific gene silencing monitored in circulating RNA
Sehgal, A., Chen, Q., Gibbings, D., Sah, D. W. Y., & Bumcrot, D. A. (2013) · RNA · doi:10.1261/rna.042507.113 · Cited by 14
Molecular Design Guided by a Local Map of Sequence Space: DNA Aptamers That Inhibit Cathepsin E
Yoshida, C., Kuniwake, A., Naimuddin, M., & Nishigaki, K. (2008) · Oligonucleotides · doi:10.1089/oli.2007.0102 · Cited by 3
Cited by
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Liposomal Formulations in Clinical Use: An Updated Review
Bulbake, U., Doppalapudi, S., Kommineni, N., & Khan, W. (2017) · Pharmaceutics · doi:10.3390/pharmaceutics9020012 · Cited by 2,156
Therapeutic siRNA: state of the art
Hu, B., Zhong, L., Weng, Y., Peng, L., Huang, Y., Zhao, Y., & Liang, X.-J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0207-x · Cited by 1,586
The current state and future directions of RNAi-based therapeutics
Setten, R. L., Rossi, J. J., & Han, S.-P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0017-4 · Cited by 1,443
Tau-targeting therapies for Alzheimer disease
Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113
Metadata
- Authors
- Zuckerman, J. E., & Davis, M. E.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-11-16
- Volume
- 14
- Issue
- 12
- Pages
- 843-856
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2176599934
- Cited by
- 424
- References
- 92
- FWCI
- 3.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.